Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $893 | 6-8 weeks | |
50 mg | $1,160 | 6-8 weeks | |
100 mg | $1,740 | 6-8 weeks |
Description | Sograzepide is an effective and highly selective Gastrin/CCK-B antagonist (IC50: 0.1 nM), has an inhibitory effect on Gastrin/CCK-A activity (IC50: 502 nM). Sograzepide replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine, and cloned human Gastrin/CCK-B receptors (Ki: 0.068, 0.62 and 0.19 nM, respectively). |
In vivo | Sograzepide (0.1 μmol/kg; intravenous injection) has an inhibition effect on pentagastrin-induced gastric acid secretion in anesthetized rats (ED50: 87?nmol/kg). Sograzepide (intravenous injection; 10 μM/kg) inhibits pentagastrin-induced acid secretion (ED50: 0.0086 μM/kg). Sograzepide (intravenous injection; p.o.) in Heidenhain pouch dogs, inhibits pentagastrin-stimulated gastric acid secretion in a dose-dependent manner (ED50: 0.018 and 0.020 μM/kg, respectively) [1][2]. |
Alias | YM-220, Netazepide, YF 476 |
Molecular Weight | 498.58 |
Formula | C28H30N6O3 |
Cas No. | 155488-25-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (200.57 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.